Analyzing Nanobiotix's P1 Head & Neck data for the radioenhancer NBTXR3 from #ASTRO2023
CEO Laurent Levy walks us through the data and makes his argument that patients' overall survival seen on NBTXR3 was greater than what would be expected from historical controls.